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treatment can signiﬁ cantly reduce the number of diabetes and CHD events. As a 
consequence, it can provide considerable reductions in the health and economic 
burden to schizophrenia patients and health care services in the Spanish setting due 
to its favourable metabolic proﬁ le.
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OBJECTIVES: A cost-utility analysis of a new antidepressant, agomelatine (Val-
doxan®) compared to generic ﬂ uoxetine and sertraline in the treatment of adult Major 
Depressive Disorders (MDD) was performed from the societal perspective and that of 
the Irish Health Service Executive (HSE). For each of these two perspectives, a separate 
analysis was performed for two different drug schemes: General Medical Services 
scheme (GMS) and the Drug Payments scheme (DP). METHODS: A Markov model 
was developed with health states for well, depressive episode, remission and death. 
The model also incorporated sleep disorders, discontinuation rates, discontinuation 
symptoms and adverse drug reactions. The time horizon of the analysis was two years. 
Remission, relapse and discontinuation rates as well as frequencies of the different 
clinical parameters were obtained from head-to-head comparative trials. Utility/disutil-
ity estimates were obtained from the literature. Costs (euros 2009) and effects were 
discounted at 4% per annum after year 1. RESULTS: From the societal perspective, 
agomelatine was dominant over both generic comparators in both drug schemes. From 
the HSE perspective, agomelatine was cost-effective compared to the two comparators 
in both drug schemes. One-way sensitivity analysis showed that the results were robust 
to uncertainty in model parameters. Probabilistic sensitivity analysis demonstrated 
that for a willingness-to-pay threshold of c45,000/QALY, agomelatine was cost-
effective compared to the two comparators in more than 93% of cases for both drug 
schemes CONCLUSIONS: From the societal perspective, agomelatine was dominant 
over generic ﬂ uoxetine and sertraline for the treatment of adult MDD in Ireland. From 
the Irish HSE perspective, agomelatine was cost-effective compared to the two com-
parators with high probability.
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OBJECTIVES: To explore the cost-effectiveness of aripiprazole in UK patients with 
bipolar I disorder (BPD). METHODS: A Markov state transition model was developed 
to estimate the cost-effectiveness of aripiprazole, post-olanzapine, compared with 
risperidone or quetiapine, the most commonly used atypicals in the UK after olanzap-
ine. Modelling was undertaken from a UK NHS perspective using discount rate of 
3.5%. The time horizon of the model was 5 years (NICE BPD Guideline). The model 
incorporated an acute manic phase and relapse prevention phase. Response to therapy 
(at least a 50% reduction in Young-Mania Rating Scale) and discontinuation in the 
acute phase were based on an indirect comparison of trials in acute manic treatment. 
Probabilities of experiencing a new manic or depressive episode or discontinuing 
treatment in the relapse prevention phase were informed by a network meta-analysis. 
Quetiapine (at time of analysis) and risperidone are not indicated for relapse preven-
tion in the UK; those patients were switched to lithium. Outpatient, hospitalization 
and drug costs were included based on published sources. a probabilistic sensitivity 
analysis (PSA) was used to examine uncertainty. RESULTS: Key drivers in the model 
are cost and quality-of-life reduction associated with acute mania. Aripiprazole is more 
effective than quetiapine in the acute phase and than lithium in the relapse prevention 
phase. Therefore, used post-olanzapine, aripiprazole gains 0.025 quality adjusted 
life-years (QALYs) and saves £3,995 compared with quetiapine and gains 0.01 QALYs 
and saves £607 compared with risperidone. Results from the PSA demonstrate 92% 
conﬁ dence that aripirazole is cost-effective versus quetiapine, and 61% conﬁ dence 
versus risperidone when using a threshold of £30,000 per QALY. CONCLUSIONS: 
Aripiprazole used post-olanzapine in the treatment of BPD is a cost-effective use of 
NHS resources compared with quetiapine and risperidone.
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OBJECTIVES: A cost-effectiveness analysis of a new antidepressant, agomelatine 
(Valdoxan®) compared to duloxetine in the treatment of Major Depressive Disorders 
(MDD) in adults was performed in a Hungarian setting from a societal perspective 
and the National Health Insurance Fund (NHIF) perspective. METHODS: A Markov 
model was adapted with health states for well, depressive episode, remission and 
death. The model also incorporated sleep disorders, discontinuation rates, discontinu-
ation symptoms and adverse drug reactions (incl. constipation, diarrhoea, dyspepsia, 
headache, nausea, somnolence, and sexual dysfunction). The time horizon was set to 
two years. An indirect comparison was run based on a meta-analysis of duloxetine 
from a literature review to document clinical parameters unavailable from completed 
trials. a prospective cost of illness study in Hungary implemented in 2009 documented 
direct and indirect costs of MDD. Utilities for each health state and disutilities for 
each clinical event were taken from the literature. The discount rate was 5% per year 
RESULTS: From the societal perspective, agomelatine was cost-saving and more effec-
tive than duloxetine. From the NHIF perspective, agomelatine resulted in 0.037 
QALYs gained compared to duloxetine with 5073 HUF as additional direct costs. One 
way sensitivity analyses showed that the results were robust to most parameter 
changes. From a societal perspective, agomelatine dominates duloxetine in 75% of 
cases and is cost-effective in 91% of cases at a willingness-to-pay threshold of 7 million 
HUF/QALY. From the NHIF perspective, agomelatine is cost-effective versus dulox-
etine in more than 90% of cases. CONCLUSIONS: In a Hungarian setting, agomela-
tine is dominant from a societal perspective and cost-effective from a NHIF perspective 
versus duloxetine. These results are robust, conﬁ rmed by sensitivity analyses.
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OBJECTIVES: Major Depressive Disorder (MDD) is a chronic illness associated with 
major burden on Quality-of -Life (QoL) and health care resources. a recent study 
estimated annual cost being c282 per European inhabitant. Adjunctive treatments with 
aripiprazole, quetiapine and olanzapine have demonstrated efﬁ cacy in patients with 
MDD that respond insufﬁ ciently to antidepressant treatment. The objective is to 
estimate the cost-effectiveness of adjunctive therapies in depressive patients failing to 
respond to antidepressant therapy in Turkey. METHODS: An economic model was 
built simulating MDD patients between major depressive episodes (MDEs) and remis-
sion over lifetime. During MDEs, patients were treated with adjunctive aripiprazole, 
quetiapine or olanzapine. Patients who did not respond at 6 weeks switched to sub-
sequent treatment lines. Comparative effectiveness between aripiprazole, quetiapine 
and olanzapine, was imputed using an indirect comparison combining 6-week pub-
lished studies. Resource use data and unit costs were obtained from Turkish studies. 
RESULTS: Over life-time, aripiprazole patients spent less time in MDEs compared to 
quetiapine (7,7 weeks) and olanzapine (7.5 weeks). Compared to Quetiapine, patients 
with aripiprazole showed improvement in QoL (+0.045 QALY) at incremental direct 
cost of 421TL. Compared to olanzapine, patients with aripiprazole dominated, 
meaning improvement of QoL (+0.042 QALY) respectively, at lower direct cost (-32 
TL), despite higher drug costs. Sensitivity analyses estimated a 87% likelihood that 
aripiprazole improved QoL at a comparable cost verus quetiapine and 88% versus 
olanzapine. CONCLUSIONS: This is the ﬁ rst lifetime health-economic model in 
Turkey taking patient heterogeneity into account when assessing QoL and costs of 
different adjunctive strategies in MDD. These results indicate that adjunctive treatment 
with aripiprazole provides health beneﬁ ts at lower costs compared to quetiapine and 
olanzapine, in patients with MDD.
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OBJECTIVES: To evaluate 24 months cost-effectiveness of risperidone long-acting 
injection (RLAI) in patients with schizophrenia enrolled in the electronic-Schizophre-
nia Treatment Adherence Registry (e-STAR) from Czech Republic. This evaluation is 
a follow-up of 12 months data presented at the European ISPOR congress (Athens 
2008). METHODS: e-STAR is an international 24-month, prospective, observational 
study in patients with schizophrenia who commenced RLAI treatment (based on SmPC 
indication). Analyzed data covered one year of retrospective (prior to RLAI initiation) 
vs. 24 months of prospective observation. a total of 607 patients have completed the 
24 months study. Assessed direct costs were: hospitalization (duration and frequency), 
antipsychotic medication and co-medication all from the payer’s perspective in 2009 
prices. Efﬁ cacy parameters included GAF (Global Assessment of Functioning) and 
CGI-S (Clinical Global Impression-Severity) scores. RESULTS: Mean annual costs/
patient increased form c2173 (1 Euro = 26 CZK) in the retrospective period to c4270 
during the ﬁ rst and 4453 during the second years of observation. Mean cost drivers 
were hospitalization (63% of total retrospective costs) and antipsychotic medication 
(90% and 91% of total prospective costs). Costs of RLAI could not be fully offset by 
signiﬁ cant reductions in hospitalization (both frequency and duration) and co-medi-
cation. Improvements in GAF and CGI scores seen at the ﬁ rst treatment year were 
maintained during year 2 of assessment. Overall GAF changed from 49.6 (baseline) 
to 74.6 (at 24 month), CGI decreased from baseline 4.61 to 2.96 (24-month). Cost-
effectiveness (costs/clinically relevant change in parameters) could also be maintained. 
More than one-third of patients achieved disease remission, resulting in acceptable 
incremental c850/patient in remission. CONCLUSIONS: Switching to risperidone 
long-acting injection in patients with treatment failure, non-compliance or intolerance 
